Key result
Compound I-6602 demonstrated improved anti-Rhinovirus activity and decreased cell toxicity compared to pirodavir, achieving a protection index >700 on HRV14 versus 250 for pirodavir.
Population
Cell cultures infected with Rhinoviruses (including HRV14) and Polioviruses
Comparison
Novel synthetic compounds vs Pirodavir (control molecule)
Design
Preclinical
Authors
Loading...
I-6602 shows superior in vitro profile versus pirodavir; leaves open in vivo efficacy and clinical translation.
Absolute Event Rate: 700% vs 250%
Novel synthetic derivatives of pirodavir demonstrate improved antiviral protection indices and lower cytotoxicity against human rhinoviruses in vitro.
Laconi et al. (2011) studied Human Rhinoviruses infection. Compound I-6602 vs. Pirodavir was evaluated on Protection index (PI) on infected cells (HRV14). Compound I-6602 demonstrated improved anti-Rhinovirus activity and decreased cell toxicity compared to pirodavir, achieving a protection index >700 on HRV14 versus 250 for pirodavir.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: